/ /
Purpose: The objective of this announcement is to notify public health and safety, law enforcement, first responders, clinicians, medical...
/ /
Purpose: The objective of this announcement is to notify public health and safety, law enforcement, first responders, clinicians, medical...
A 2018 special report published by the Centers for Disease Control and Prevention (CDC) found that, among people aged...
/ /
The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to...
This Act intends to avoid the missed opportunities associated with the wide-ranging expenditures of the tobacco settlement funds and...
/ /
The American Medical Association convened two task forces between 2014–2019 that have provided actionable and measurable recommendations and principles...
/ /
In its continuing effort to keep prescription drug monitoring programs (PDMPs) and other stakeholders apprised of new and changing...
Of the 54 PDMPs in the United States, 39 were established since 1999 and 20 of those in the...
Etodesnitazene — New Synthetic Opioid Identified During Forensic Death Investigations in the United States and Canada December 14, 2021
New Synthetic Opioid Protonitazene Increasing in Prevalence as “Nitazenes” Gain Traction Across the United States and Canada December 14, 2021
Adverse Effects Linked to Next Generation Opioids Reported in Patients Presenting to Emergency Departments After Suspected Opioid Overdose December 10, 2021
Model Syringe Services Program Act December 9, 2021
Federal Register: Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I December 7, 2021
National Association of Drug Diversion Investigators Federal Tax ID: 52-1660752 / DUNS Number: 073539913
Copyright © 2022 - NADDI. All Rights Reserved. Privacy Policy / Trademark Policy / Copyright Policy / Refund Policy
